CYBA C242T polymorphism is associated with obesity and diabetes mellitus in Brazilian hypertensive patients

Imagem de Miniatura
Arquivos
art_KRIEGER_CYBA_C242T_polymorphism_is_associated_with_obesity_and_2012_eng.pdf (100.8 KB)
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2012
Editora
WILEY-BLACKWELL
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
SCHREIBER, R.
FERREIRA-SAE, M. C.
TUCUNDUVA, A. C.
MILL, J. G.
COSTA, Felipe O.
FRANCHINI, K. G.
NADRUZ JR., W.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
DIABETIC MEDICINE, v.29, n.7, p.E55-E61, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Diabet. Med. 29, e55e61 (2012) Abstract Aims The CYBA C242T polymorphism has been associated with cardiovascular phenotypes such as hypertension and atherosclerosis, but available data are conflicting. This report investigated the impact of this variant on hypertension and metabolic determinants of cardiovascular risk in a large Brazilian sample. Methods We cross-sectionally evaluated 1856 subjects (826 normotensive subjects and 1030 hypertensive patients) by clinical history, anthropometry, laboratory analysis and genotyping of the CYBA C242T polymorphism. Results Genotype frequencies in the whole population were consistent with the HardyWeinberg equilibrium and genotype distributions were not different between hypertensive and normotensive subjects. Hypertensive patients with the CC genotype presented lower fasting plasma glucose levels (5.9 +/- 0.1 vs. 6.2 +/- 0.1 mmol/l, P = 0.020) and waist circumference (94.5 +/- 0.6 vs. 96.3 +/- 0.6 cm, P = 0.028) than CT + TT ones. Similarly, the prevalence of diabetes mellitus and obesity was also lower in hypertensive patients carrying the CC genotype (16% vs. 21%, P = 0.041; 36% vs. 43%, P = 0.029, respectively). In addition, multiple and logistic regression analysis demonstrated that the CYBA C242T polymorphism was associated with glucose levels, waist circumference, obesity and diabetes mellitus in hypertensive patients independently of potential confounders. Conversely, in normotensive subjects, no significant difference in studied variables was detected between the genotype groups. Conclusions These data suggest that the T allele of the CYBA C242T polymorphism may be used as a marker for adverse metabolic features in Brazilian subjects with systemic hypertension.
Palavras-chave
diabetes mellitus, hypertension, metabolic profile, single nucleotide polymorphism
URI
https://observatorio.fm.usp.br/handle/OPI/237
Referências
  1. Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200
  2. Cahilly C, 2000, CIRC RES, V86, P391
  3. Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
  4. Chang Yi-Cheng, 2010, Am J Transl Res, V2, P316
  5. Di Castelnuovo A, 2008, THROMB HAEMOSTASIS, V99, P594, DOI 10.1160/TH07-08-0480
  6. Elliott WJ, 2007, LANCET, V369, P201, DOI 10.1016/S0140-6736(07)60108-1
  7. Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
  8. Fan M, 2006, AM HEART J, V152, P538, DOI 10.1016/j.ahj.2006.02.018
  9. Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]
  10. Griendling KK, 2004, HEART, V90, P491, DOI 10.1136/hrt.2003.029397
  11. Inoue N, 1998, CIRCULATION, V97, P135
  12. Ito D, 2000, STROKE, V31, P936
  13. Kim KI, 2007, INT J CARDIOL, V123, P18, DOI 10.1016/j.ijcard.2006.11.105
  14. Leslie WS, 2007, QJM-INT J MED, V100, P395, DOI 10.1093/qjmed/hcm044
  15. Matsunaga-Irie S, 2004, DIABETES CARE, V27, P303, DOI 10.2337/diacare.27.2.303
  16. Milagro FI, 2006, OBESITY, V14, P1118, DOI 10.1038/oby.2006.128
  17. Moreno MU, 2006, J HYPERTENS, V24, P1299, DOI 10.1097/01.hjh.0000234110.54110.56
  18. Moreno Maria de Ujue, 2011, Front Biosci (Elite Ed), V3, P1467
  19. Ochoa MC, 2008, J PHYSIOL BIOCHEM, V64, P127, DOI 10.1007/BF03168240
  20. Paravicini TM, 2008, DIABETES CARE, V31, pS170, DOI 10.2337/dc08-s247
  21. Pereira AC, 2004, KIDNEY INT, V65, P1026, DOI 10.1111/j.1523-1755.2004.00479.x
  22. Qi Y, 2004, NAT MED, V10, P524, DOI 10.1038/nm1029
  23. Sales ML, 2010, AM J HYPERTENS, V23, P649, DOI 10.1038/ajh.2010.24
  24. Sales ML, 2007, J HUM HYPERTENS, V21, P504, DOI 10.1038/sj.jhh.1002170
  25. San Jose Gorka, 2008, Clin Sci (Lond), V114, P173, DOI 10.1042/CS20070130
  26. San Jose G, 2004, HYPERTENSION, V44, P163, DOI 10.1161/01.HYP.0000134790.02026.e4
  27. Schreiber R, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-114
  28. Shimo-Nakanishi Y, 2004, ATHEROSCLEROSIS, V175, P109, DOI 10.1016/j.atherosclerosis.2004.01.043
  29. Tirosh A, 2008, DIABETES CARE, V31, P2032, DOI 10.2337/dc08-0825
  30. Zalba G, 2005, ANTIOXID REDOX SIGN, V7, P1327, DOI 10.1089/ars.2005.7.1327

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13